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Context: Steroid sulfatase (STS) cleaves the sulfate moiety off steroid sulfates, including dehydro-
epiandrosterone (DHEA) sulfate (DHEAS), the inactive sulfate ester of the adrenal androgen pre-
cursor DHEA. Deficient DHEA sulfation, the opposite enzymatic reaction to that catalyzed by STS,
results in androgen excess by increased conversion of DHEA to active androgens. STS deficiency
(STSD) due to deletions or inactivatingmutations in the X-linked STS genemanifests with ichthyo-
sis, but androgen synthesis and metabolism in STSD have not been studied in detail yet.
Patients and Methods: We carried out a cross-sectional study in 30 males with STSD (age 6–27 y;
13 prepubertal, 5 peripubertal, and 12 postpubertal) and 38 age-, sex-, and Tanner stage-matched
healthy controls. Serum and 24-hour urine steroid metabolome analysis was performed by mass
spectrometry and genetic analysis of the STS gene by multiplex ligation-dependent probe ampli-
fication and Sanger sequencing.
Results: Genetic analysis showed STS mutations in all patients, comprising 27 complete gene de-
letions, 1 intragenic deletion and 2 missense mutations. STSD patients had apparently normal
pubertal development. Serum and 24-hour urinary DHEASwere increased in STSD, whereas serum
DHEA and testosterone were decreased. However, total 24-hour urinary androgen excretion was
similar to controls, with evidence of increased 5-reductase activity in STSD. Prepubertal healthy
controls showed a marked increase in the serum DHEA to DHEAS ratio that was absent in post-
pubertal controls and in STSD patients of any pubertal stage.
Conclusions: In STSD patients, an increased 5-reductase activity appears to compensate for a
reduced rate of androgen generation by enhancing peripheral androgen activation in affected
patients. In healthy controls, we discovered a prepubertal surge in the serumDHEA toDHEAS ratio
thatwas absent in STSD, indicativeof physiologically up-regulated STS activity beforepuberty. This
may represent a fine tuning mechanism for tissue-specific androgen activation preparing for the
major changes in androgen production during puberty. (J Clin Endocrinol Metab 101: 2545–2553,
2016)
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Sulfation has been identified as a critical step in regu-lating the balance between conversion of the princi-
pal androgen precursor dehydroepiandrosterone (DHEA)
to active androgens and its inactivation through sulfation
to DHEA sulfate (DHEAS) (Figure 1). The latter reaction
ismainly catalyzed byDHEA sulfotransferase, SULT2A1,
and recent reports have revealed this enzyme as a crucial
switch controlling androgen activation. Disruption of
DHEA sulfation due to inactivating mutations in the hu-
man gene encoding PAPSS2, a crucial cofactor of
SULT2A1, has been shown to result in increased androgen
activation and a polycystic ovary syndrome (PCOS) phe-
notype in both homozygous and heterozygous individuals
(1, 2).
Consequently, it appears reasonable to assume that a
defect in DHEA desulfation catalyzed by the enzyme ste-
roid sulfatase (STS), may result in reduced sex steroid lev-
els. STS also known as aryl sulfatase C, is a membrane-
bound microsomal enzyme and member of a highly
conserved family of aryl sulfatases. Members of that en-
zyme family catalyze the cleavage of the sulfate moiety
from a variety of substrates, including conjugated steroids
and other hormones, proteoglycans, posttranslationally
modified proteins and aromatic compounds (for compre-
hensive reviews, see Refs. 3, 4). STS hydrolyzes the sulfate
moiety of sulfated 3-hydroxysteroids and has a high sub-
strate affinity toDHEAS, themost abundant prohormone
in the human circulation.
A previous study in healthy adult men has suggested
that STS has no significant impact on systemic androgen
reactivation from DHEAS. After iv infusion of DHEAS,
participants did not show any increase in circulating con-
centrations of DHEA or active androgens whereas oral
administration of nonsulfated DHEA resulted in signifi-
cant increases of both DHEAS and active androgens (5).
The STS gene is localized on the short arm of the X-
chromosome (Xp22.3), which is part of the pseudoauto-
somal region escaping X-inactivation (6). Genetic abnor-
malities of the STS gene cause STS deficiency (STSD)
resulting in the skin condition X-linked ichthyosis (XLI),
a common inborn error of metabolism with a reported
prevalence of 1:1500 to 1:6000 males (7, 8). STSD/XLI is
characterized by thickening of the epidermis with large
brown scales of the skin, which are thought to be due to
accumulation of sulfated sterols, mainly cholesterol sul-
fate, in the stratum corneum of the epidermis (9–11).
Only very few studies in men with XLI/STSD have ex-
plored sex steroid metabolism but without providing de-
tailed clinical information (12–14), and there is no previ-
ous study assessing pubertal development and androgen
production at the key developmental stages of adrenarche
and puberty in these patients. However, severe androgen
deficiency has not been reported yet in XLI/STSD, and
infertility is not part of its clinical spectrum, with the ex-
ception of patients with larger genomic deletions affecting
other genes impacting on reproduction (7).
In this study, we have explored androgen generation
andmetabolism in a large cohort of boys, adolescents and
young men with XLI/STSD with genetically defined mu-
tations confined to the STS locus only, to investigate
whether loss of STS function impacts on androgenbalance
during adrenarche and puberty.
Materials and Methods
Patients and study protocol
Inclusion criteria were age between 6 and 30 years and an
established diagnosis of XLI/STSD, either based on clinical,
biochemical or genetic testing. Exclusion criteria for both pa-
tients and sex- and age-matched healthy volunteers were
chronic severe disease potentially affecting DHEA secretion
(eg, rheumatoid arthritis, ulcerative colitis, cancer), steroid
treatment during the preceding 12 months, including steroid
inhalers, intake of other drugs known to alter steroid metab-
olism, and impairment of liver or kidney function due to con-
comitant disease or medication.
The Warwickshire Research Ethics Committee provided ap-
proval of the study protocol. All participants provided written
informed consent; in individuals under 18 years, additional as-
sent from at least 1 parent was obtained. On the study day,
participants arrivedafter anovernight fast at the clinical research
facility. A clinical history was taken and participants underwent
a physical examination, including a dermatological inspection
and a detailed assessment of pubertal development including
Tanner stages and testicular volume determined by referring to
a Prader orchidometer. Anthropometric data (height, weight,
body mass index [BMI]) were recorded. Blood samples were
obtained formeasurement of serum steroid hormones and germ-
line DNA extraction. All participants collected a 24-hour urine
for evaluation of the steroid metabolome.
Genetic analysis
STS gene deletions are the underlying abnormality in 90% of
patients with XLI. Therefore, we usedmultiplex ligation-depen-
dent probe amplification (MLPA) as the primary approach to
genetic analysis. The MLPA assay was designed by MRC-Hol-
land bv, comprising 11 probes specifically targeting the coding
Figure 1. Androgen activation pathway from dehydroepiandro-
sterone (DHEA), which is either inactivated to DHEA sulphate (DHEAS)
or activated via androstenedione and testosterone to the most
powerful androgen, 5a-dihydro-testosterone. HSD3B, 3beta-
hydroxysteroid dehydrogenase; HSD17B, 17beta-hydroxysteroid
dehydrogenase; SRD5A, 5alpha-reductase; SULT2A1, DHEA
sulfotransferase; STS, steroid sulfatase.
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exons of the STS gene to identify partial or complete STS gene
deletions. In addition, the assay also targets the coding exons of
theneighboringKAL1 locus aswell as theHDHD1 locus located
centromeric and telomeric from STS, respectively. MLPA was
performed using standard reaction conditions according to the
manufacturer’s protocol. In patients with no abnormalities on
MLPAanalysis, PCR amplification of the entire coding region of
the STS gene (9 fragments), including intron/exon boundaries
from genomic DNA, was performed (for primer sequences see
SupplemetalTable1).Direct sequencingwas carriedoutusingan
ABI3730 sequencer (Applied Biosystems Inc), and sequencing
analysis was carried out using the CLC Main Workbench soft-
ware (CLC bio).
Serum and urine steroid measurements
Serum steroids were measured by liquid chromatography-
tandem mass spectrometry (LC-MS/MS) employing a Waters
Xevomass spectrometer with Acquity uPLC system as described
previously (2, 15). In brief, unconjugated serum steroids (DHEA
and testosterone) were extracted from 200 L of serum via liq-
uid-liquid extraction using methyl tert-butyl ether. After extrac-
tion, oxime derivatization of carbonyl groups was performed, a
modification that provides enhanced sensitivity of DHEA mea-
surement (16). TandemMSof the steroid oximes employed elec-
trospray ionization in positive mode.
DHEAS and cholesterol sulfate were extracted from serum in
a method adapted form Chadwick et al (17). In brief, 20 L of
serumwere taken, and internal standardwas added, followed by
20 L of 0.1mM zinc sulfate for protein precipitation. Subse-
quently, 100 L of acetonitrile was added, the sample centri-
fuged, and 100 L of the supernatant were transferred to a new
plate, evaporated, and reconstituted in methanol/water before
LC-MS/MS analysis. Measurement of serum DHEAS and cho-
lesterol sulfate was performed in employed electrospray ioniza-
tion negative mode.
Steroids were identified and quantified via comparison of
retention time and 2 mass transitions (multiple reaction moni-
toring) to an authentic standard. Each steroid was quantified
relative to a deuterated internal standard (testosterone-d3,
DHEA-d6, or DHEAS-d2).
Urinary steroidmetabolite excretion analysiswas carriedout by
quantitative gas chromatography-mass spectrometry (GC-MS) in
selected-ion-monitoring analysis mode, as described previously
(18). In brief, urinary steroids were enzymatically released from
conjugation, with subsequent recovery of the hydrolyzed steroids
by C18 solid phase extraction using Sep-Pak columns (Waters),
followed by chemical derivatization before GC-MS-selected-ion-
monitoring analysis. We quantified systemic 5-reductase activity
by determining the ratio of the 5-reduced glucocorticoid metab-
olite5-tetrahydrocortisol (5THF)over its5-reducedmetabolite
THF.We alsomeasured urinary DHEA, which represents the sum
of urinary DHEA and DHEAS excretion and cannot be distin-
guished with this method as the sulfate group is removed by a hy-
drolysis stepbefore themeasurement.However,wehavefoundthat
more than 99%of urinaryDHEAoriginates fromDHEAS, ie, pro-
portionate to their respective circulating serum concentrations in
the nanomolar and micromolar range, respectively (2). Thus, for
clarity, we have labeled the sum of urinary DHEA and DHEAS in
results and figures as urinary DHEAS.
Statistical analysis
A nonparametric test (Mann-Whitney-Wilcoxon) was used
to compare the2 independent parameters fromeach cohort (con-
trol vs STSD).P .05was assumed to be statistically significant.
Data were expressed as median (interquartile range [boxes]
and 10th–90th percentile [whiskers] ranges). The software
GraphPad Prism was used for analysis.
Results
Patient characteristics
We recruited 30 patients with STSD and 38 healthy
volunteers (controls). STSD patients and controls did not
differ with regard to weight standard deviation score
(SDS) (controls vs STSD 0.58  1.0 vs 0.31  1.3, P 
.42), height SDS (0.04 1.2 vs 0.37 1.1, P .92), and
BMI SDS (0.66  1.0 vs 0.09  1.4, P  .37).
All patients had clinically typical dermatological
findings of XLI with different degrees of severity. In
most the STSD patients, the diagnosis had been estab-
Table 1. Clinical Characteristics of the STSD Cohort
Patient
Number
Age
(y)
BMI
(kg/
m2)
Tanner
Pubertal
Stages
Testicular
Volume
P G A
Left
(mL)
Right
(mL)
Prepubertal P01 6.2 13.7 1 1 1 2 2
P02 6.7 23.0 1 1 1 n.d. 2
P03 6.9 16.2 1 1 1 2 2
P04 7.5 15.0 1 1 1 3 3
P05 7.6 18.1 1 1 1 3 3
P06 9.1 15.2 1 1 1 2 2
P07 9.2 14.6 1 2 1 3 3
P08 9.2 24.1 1 1 1 3 3
P09 10.0 16.5 1 1 1 3 3
P10 10.8 16.1 1 1 1 3 3
P11 11.0 14.6 1 1 1 3 3
P12 11.1 17.3 1 1 1 2 2
P13 11.2 23.2 1 1 1 3 3
Peripubertal P14 11.7 17.5 1 2 1 4 3
P15 12.8 18.6 2 2 1 4 4
P16 13.3 16.6 1 2 1 3 4
P17 13.4 14.8 1 2 1 5 4
P18 13.4 16.9 1 2 1 5 5
Postpubertal P19 14.3 19.3 5 5 2 10 15
P20 15.8 17.8 5 5 2 20 20
P21 15.8 23.5 5 4 2 20 20
P22 15.9 20.7 5 5 2 25 25
P23 16.3 24.3 5 5 2 15 15
P24 18.0 15.6 5 5 2 20 20
P25 19.6 25.0 6 5 2 25 20
P26 20.8 19.3 5 5 2 20 20
P27 22.9 23.9 6 5 2 20 20
P28 24.8 25.7 6 5 2 25 25
P29 26.5 24.9 5 5 2 20 20
P30 26.6 27.47 6 5 2 20 20
Tanner stages: P, pubic hair; G, genitalia; A, axillary hair; n.d., not
detected.
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lished based on clinical findings only (n  20). In 7
patients, an additional lymphocyte assay for STS activ-
ity had been performed, which had shown decreased
activity.Only 3 of 30 patients had previously undergone
genetic testing for confirmation of diagnosis.
There was no history of consanguinity in the affected
families. We recruited 4 pairs of siblings with STSD and 3
affected brothers from a single family.
Eleven patients had additional conditions, mostly
atopic disease such as mild asthma (n  6), hay fever
(n  4), eczema (n  1), or multiple allergies (n  1); 1
patient had been diagnosed with attention deficit hy-
peractivity disorder.
Pubertal development
Thirteen STSD patients were clinically prepubertal
with testicular volumes less than or equal to 4 mL and
prepubertalTanner stages. Fivepatientswereperipubertal
with testicular volumes between 4 and 14mL; the remain-
ing 12 STSD patients were postpubertal with testicular
volumes more than 15 mL and physically fully developed
secondary characteristics as assessed by Tanner stages
(Table 1).
One STSD patient (age 6.7 y) was found to have a
unilateral undescended testicle and was subsequently
referred for surgical treatment by orchidopexy. No pa-
tient had delayed puberty as defined by pubertal onset
after the age of 14 years; pubertal progression according
to Tanner stages and testicular volumes were appropri-
ate for age in all participants (Table 1).
For further analysis, subjects were allocated to 3 sub-
groups based on their pubertal progression as stated
above: prepubertal STSD n  13, controls n  15;
peripubertal STSD n  5, controls n  5; and postpu-
bertal STSD n 12, controls n 19. Statistical analysis
has been performed in all 3 subgroups (Table 2), but for
the purpose of clarity, only the pre- and postpubertal
subgroups have been visualized in Figures 2 and 3.
Genetic analysis
Genetic analysis confirmed abnormalities within the
STS gene in all patients. A total of 27 of 30 patients had
Table 2. Median (Interquartile Range) of Serum and Urinary Steroids in STSD Patients and Controls Within the 3
Different Subgroups in STSD Patients (Prepubertal, n  13; Peripubertal, n  5; Postpubertal, n  12) and Healthy
Sex- and Age-Matched Controls (Prepubertal, n  15; Peripubertal, n  5; Postpubertal, n  19)
STSD Controls P Value
Serum DHEA (nmol/L)
All 6.0 (3.1, 9.1) 20.0 (13.1, 31.7) .0001
Prepubertal 6.6 (2.4, 7.6) 20.1 (14.2, 32.8) .0001
Peripubertal 5.7 (4.8, 7.4) 11.3 (8.4, 22.3) .110
Postpubertal 9.0 (6.8, 14.2) 18.4 (11.1, 29.9) .004
Serum DHEAS (mol/L)
All 5.1 (4.1, 7.5) 3.5 (1.4, 9.6) .373
Prepubertal 4.5 (2.0, 5.0) 1.4 (0.7, 3.0) .014
Peripubertal 6.2 (4.6, 7.1) 3.5 (3.2, 3.7) .343
Postpubertal 7.1 (6.2, 9.6) 10.1 (6.6, 13.0) .227
Serum DHEA to DHEAS ratio
All 0.9 (0.1, 1.4) 4.9 (2.3, 16.9) .0001
Prepubertal 0.4 (0.1, 1.0) 15.8 (8.5, 36.9) .0001
Peripubertal 0.6 (0.2, 1.03) 3.0 (2.3, 6.5) .029
Postpubertal 1.2 (0.1, 1.6) 2.6 (1.3, 4.5) .010
Serum testosterone (nmol/L)
All 4.0 (0.4; 11.0) 10.1 (0.4, 17.6) .145
Prepubertal 0.4 (0.4, 0.7) 0.4 (0.4, 1.22) .296
Peripubertal 4.0 (1.5, 6.5) 6.3 (2.2, 11.1) .685
Postpubertal 11.8 (10.4, 15.6) 19.4 (15.3, 25.0) .008
Urinary androsteroneetiocholanolone
excretion (g/24 h)
All 604 (231, 3526) 780 (235, 4067) .588
Prepubertal 237 (177, 415) 247 (96, 413) .957
Peripubertal 466 (226, 567) 456 (256, 1652) .111
Postpubertal 4055 (2722, 4779) 4193 (3184, 5461) .521
Urinary 5THF to THF ratio
All 2.3 (1.8; 3.2) 1.2 (1.0; 1.7) .0001
Prepubertal 1.9 (1.6; 3.1) 1.1 (0.9; 1.3) .040
Peripubertal 3.2 (3.2; 3.8) 1.2 (1.0; 1.6) .016
Postpubertal 2.7 (1.9; 3.4) 1.2 (1.1; 2.2) .003
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a complete deletion of the STS gene and the adjacent
HDHD1A gene. There was no evidence for deletion of
further coding regions at the Xp22.31/32 locus; in par-
ticular, we did not identify KAL1 gene deletions in any
of the included patients (Supplemental Figure 1A). One
patient (P16) had a deletion of exon 7 only (Supple-
mental Figure 1B). In 2 brothers therewere no abnormal
findings in the MLPA analysis and subsequent Sanger
sequencing of the STS gene revealed a hemizygous non-
synonymous missense mutation in exon 9 (Supplemen-
tal Figure 1C) encoding for p.R454C, a cytosine to thy-
midine change at position g.114,414 resulting in the
replacement of arginine to cysteine on the protein level.
This mutation has previously been
reported in a patient with XLI (19).
Steroid metabolome analysis
Serum DHEA was significantly
lower in the pre- and postpubertal
STSD subjects than in sex- and age-
matched healthy controls (Figure
2, A and B). Conversely, serum
DHEASwas higher in STSD than in
controls, albeit only significantly
different in the prepubertal sub-
group. However, 24-hour urinary
DHEAS excretion in both STSD
subgroups was markedly elevated
and significantly higher than in
controls (Figure 2, A and B).
Of note, the ratio of serum
DHEA to DHEASwas significantly
higher before puberty in healthy
controls (Figure 2C). By contrast
the serum DHEA to DHEAS ratio
was persistently low in STSD pa-
tients of all subgroups (Figure 2C).
Serum testosteronewas at age-ap-
propriate low levels in all prepuber-
tal subjects (Figure 3). After puberty,
serum testosterone concentrations
were significantly lower in STSD pa-
tients than in sex- and age-matched
controls. However, 24-hour urinary
excretion of the 2 major metabolites
of active androgens, androsterone
and etiocholanolone, did not differ
between STSD and controls (Figure
3). Further analysis of the urinary
steroid metabolome revealed a sig-
nificant increase in the ratio of the
5-reduced glucocorticoid metabo-
lite 5THF over THF, indicative of
an increase in net 5-reductase activity and hence an en-
hanced peripheral androgen activation rate in all sub-
groups of STSD patients as compared with controls.
Discussion
Here,wehave investigated androgenmetabolismandgen-
eration and pubertal development in a large, genetically
fully characterized cohort of patients with STSD/XLI.We
found no gross abnormalities regarding pubertal progres-
sion and development in children and adolescents with
STSD. Their steroid metabolome was indicative of mild
Figure 2. Serum and urinary DHEA and DHEAS in patients with STSD and healthy sex- and age-
matched controls. A and B, Levels of serum DHEA and DHEAS, their ratio, reflective of STS
activity, as well as the 24-hour urinary excretion of DHEAS. A, Data from the prepubertal
subgroup (STSD, n  13; controls, n  15). B, Data from the postpubertal subgroup (STSD,
n  12; controls, n  19). C, Ratio of serum DHEA/DHEAS, reflective of STS activity, is visualized
as a function over age (top) (STSD patients; n  30; gray circles; and healthy controls; n  38;
open circles).
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androgen deficiency, with significantly lower circulating
concentrations of DHEA and testosterone. However,
these appear to be compensated for by enhanced tissue-
specific androgen activation including increased net 5-
reductase activity observed in our cohort, resulting in total
androgen metabolite excretion rates that did not differ
significantly between STSD and healthy controls.
Wehave genetically characterized the entire cohort and
found abnormalities of the STS gene in all patients. Com-
plete deletions were detected in 27 of 30 patients, in keep-
ing with previous reports describing deletions as the
commonest mutation type in XLI/STSDwith an incidence
of 80%–90% (6, 20). Importantly, deletions of the neigh-
boring KAL1 gene resulting in Kallmann syndrome with
anosmic hypogonadotropic hypogonadismwere not pres-
ent in this cohort. Similarly, other forms of contiguous
gene deletion syndromes frequently described in patients
withXLI (21, 22),werenotdetected, hence the changeswe
found can only be associated with
the loss of STS gene function. All
our patients with complete STS dele-
tions had a concurrent deletion of
theHDHD1geneupstreamof theSTS
locus, which is a previously reported
feature inmost patientswith complete
STS deletions (23, 24). HDHD1 en-
codes for a pseudouridine-5-phos-
phatase involved inRNAmetabolism,
and its molecular function has been
described in detail only recently (24).
Haloacid Dehalogenase-like Hydro-
lase domain-containing 1 (HDHD1)
dephosphorylates pseudouridine 5-
phosphate, a modified RNA nucleo-
tide present in tRNAs, rRNAs, and
smallnuclearRNAs;pseudouridine is
excreted in urine and serves as a bio-
marker for certain cancers (25). The
importance of HDHD1 in normal
physiology is not well understood;
an Hdhd1 knockout mouse has not
yet been reported.One can speculate
that HDHD1 contributes to some
phenotypic features observed in pa-
tients with XLI; however, detailed
genotype-phenotype studies are
lacking partially due to insufficient
genetic characterization of XLI pa-
tients of earlier cohorts. Preumont et
al (24) have previously speculated
that the absence of pseudouridine 5-
phosphatase activity may contribute
to the development of testicular can-
cer and cryptorchidism as this has not been observed in
patients with missense mutations or partial deletions of
the STS gene. The one patient with an undescended testis
in our cohort also had a HDHD1 deletion. However, at
present there is no conclusive evidence for functional in-
volvement of HDHD1 in testicular descent.
One patient in our cohort had a partial deletion of exon 7
of the STS gene. Although partial STS deletions have been
reported inXLI (26, 27), the deletionof exon7appears tobe
a novel finding. In addition, 2 brothers in our study carried
the known p.R454C missense mutation, previously de-
scribed in a patient with XLI; in vitro functional analysis
employing radiolabeled 3H-DHEA assays with patient leu-
kocytes demonstrated reduced STS activity (19).
Pubertal development and progression was not abnor-
mal in this cohort of STSD patients; Tanner stages, tes-
ticular volumes and height SDS did not differ from con-
Figure 3. Active androgens and their metabolism of patients with STSD (n  30) compared with
healthy male controls (n  38). Box and whisker plots depicting median, interquartile range, and
10th–90th percentile are used to visualize serum testosterone (left), the sum of 24-hour urinary
excretion of the active androgen metabolites androsterone and etiocholanolone (middle), and
the ratio of urinary 5THF to THF reflective of net 5-reductase activity (right). A, Data for the
prepubertal subjects (STSD, n  13; controls, n  15). B, Results in the postpubertal subgroup
(STSD, n  12; controls, n  19).
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trols. The onset of pubertal changes reported by the STSD
patients in our cohort was between 11 and 11.5 years,
which is considered to be within the normal range of pu-
bertal onset in males (28, 29). However, our cohort in-
cluded 5 boys with STSD who were clinically at the be-
ginning of puberty according to their testicular volume
and Tanner stages. Of those, 3 had not developed any
pubic hair by the age of 13, which is somewhat late. To
investigate in more detail whether the onset of pubertal
development in STSD boys is normal or delayed would
require the prospective observation of a cohort of prepu-
bertal individuals with STSD. None of our STSD patients
had children at the time of study participation. However,
wehave obtainedpedigrees in 22/30 STSDpatients,which
showed a classical x-linked recessive inheritance of XLI,
with maternal grandfathers and great-grandfathers af-
fected by XLI. This, in line with previous studies in pa-
tients with XLI (for review, see Ref. 7), suggests that
infertility is not part of the spectrum in STSD.
Previous studies on steroid production in STSD have
mostly focused on cholesterol sulfate and DHEAS; the
latter was not consistently reported as elevated, perhaps
due to the different methodologies employed for steroid
quantification (Table 2). Our study is the first to employ
24-hour urine steroid metabolome analysis by GC-MS
and serum steroid analysis by LC-MS/MS to comprehen-
sively analyze androgen generation and metabolism in
STSD. Previously, the most detailed information was
available from an adult Danish cohort of 20 XLI patients
(12). Although no detailed information on physical and
pubertal development was provided, the investigators
found biochemical evidence of mild androgen deficiency
with increased levels of DHEAS, suggesting an effect of
STS on peripheral sex steroid activation. In addition, LH
was higher in STSD than in 40 matched controls, suggest-
ing compensatory activation of the hypothalamic-pitu-
itary-gonadal axis. Our study is the first to cover the com-
plete age range from prepuberty to young adulthood with
detailed information on pubertal phenotype and geno-
type. The latter enabled us to exclude any effect of con-
tiguous gene deletions on the observed changes in steroid
concentrations. Our results in children and adolescents
with STSD are in keeping with those in the Danish adult
cohort (12), indicating the presence of mild androgen
deficiency.
Urinary steroid metabolome analysis in our STSD co-
hort demonstrated normal overall androgen metabolite
excretiondespite lower concentrationsofDHEAavailable
for peripheral androgen inactivation. Our finding of en-
hanced 5-reductase activity, which leads to increased
activation of testosterone to 5-dihydrostestosterone,
suggests the presence of a compensatorymechanismcoun-
teracting a slightly lower androgen production rate. In-
creased 5-reductase activity is frequently observed in an-
drogen excess conditions like adult PCOS (30–33), but
not in childrenwith premature adrenarche (34). Stewart et
Table 3. Summary of Previous Studies Investigating Circulating Steroid Concentrations in Patients With STSD
Study Subjects Findings in Blood Samples
Steroid
Quantification
by
Sánchez-Guijo et
al (10)
12 STSD, 19 controls
adult age
Increased levels of cholesterol sulfate, 16-OH-DHEAS,
DHEAS, androstenediol sulfate, androsterone sulfate, DHT
sulfate, and progestin sulfates in STSD
LC-MS/MS
Delfino et al (14) 33 STSD, 33 controls
age 3–70 y
DHEAS increases during puberty but not significantly;
cholesterol sulfate persistently elevated
GC-MS
Milone et al (13) 15 STSD, 15 controls
age 22–33 y
DHEAS elevated when measured with GC-MS, no difference
found with RIA
GC-MS and RIA
Ruokonen et al
(40)
6 STSD, 6 controls
adult age
Normal testosterone and LH; significantly increased sulfated
pregnenolone, 17-hydroxypregnenolone,
dehydroepiandrosterone, and 5-androstene-3,17-diol
and decreased corresponding unconjugated steroids;
increases in testosterone, 17-hydroxyprogesterone, and
estradiol were similar in STSD and controls after hCG
stimulation
RIA
Lykkesfeldt et al
(12)
20 STSD (age 20–60
y) 100 controls
(age 20–70 y)
Nonsignificant trend towards higher DHEAS in STSD; no
decline with age; lower levels of androstenedione and
17-estradiol in STSD; higher LH in STSD
RIA
Muskiet et al
(41)
7 STSD, 20 controls
adult age
DHEAS normal in 6 of 7 STSD patients GC-MS
Epstein et al (11) 7 STSD patients Cholesterol sulfate persistently increased in all subjects,
DHEAS frequently but not consistently high
GC-MS
Ruokonen et al
(42)
5 STSD, 10 controls
adult age
DHEAS, pregnenolone sulfate, and 5-androstene-3,
17-diol sulfate not significantly higher in STSD
RIA
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al proposed the hypothesis that increased 5-reduction in
PCOS comes first in a pathophysiological chain of events
leading to enhanced hepatic cortisol clearance, with
compensatory hypothalamic-pituitary-adrenal axis acti-
vation and enhanced adrenal androgen secretion (30). The
underlying cause for the increase of 5-reductase activity,
either a priori or as a secondary event, is still unknown.
Our study is the first to provide information on serum
DHEA concentrations in STSD, which has not been
measured in any of the previous studies (Table 2) and the
results in our cohort demonstrate lowDHEA and increased
DHEAS. Previous studies indicate minimal contribution of
STS to reactivation of DHEAS to DHEA in adults (5) and a
dissociation of DHEA and DHEAS is rarely observed (35).
Results in our STSD cohort reveal a small but detectable
impact of disrupted STS activity to circulating DHEA and
DHEAS levels. However, the results from this study do not
suggest that patients with STSD require routine endocrine
follow-up as they seem to progress through pubertywithout
significant abnormalities.
We also report, for the first time, a significantly in-
creased ratio of serum DHEA over serum DHEAS in
healthy prepubertal children that decreases steeply after
puberty. This prepubertal increase in the DHEA to
DHEAS ratio is absent in STSD patients, indicating that
this previously unknown phenomenon is due to a prepu-
bertal, physiological increase in STS activity. Little is
known about normal physiological regulation of STS,
with some evidence of cytokine-mediated changes in STS
expression and activity (36, 37). In addition, it is possible
that cofactors of STS could exhibit age- and sex steroid-
dependent changes. Sulfatasemodifying factor1 is respon-
sible for the posttranslational modification of a highly
conserved cysteine residue to a unique formylglycine res-
idue in the active site of the STS enzyme that is crucially
required for catalytic activity; changes in sulfatase modi-
fying factor 1 impact on STS activity with human inacti-
vating mutations resulting in multiple sulfatase deficiency
(38, 39).
In summary, we have demonstrated by steroidmetabo-
lome analysis that the impact of STSD on androgen gen-
eration is small, resulting in onlymild androgen deficiency
that is apparently compensated for by up-regulation of
peripheral androgen activation. This suggests that the sul-
fotransferase reaction inactivating DHEA to DHEAS is
the predominant switch regulating the balance between
DHEA activation and inactivation, with significant clin-
ical implications (1, 2). We found evidence for a dissoci-
ation of DHEA and DHEAS before puberty in healthy
controls that was absent in STSD, suggestive of signifi-
cantly increased STS activity during the prepubertal pe-
riod in healthy individuals.We suggest that this represents
a mechanism to fine tune tissue-specific androgen action,
priming the body for the subsequent changes in gonadal
androgen production during puberty.
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